Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Galobio
Buenos Aires, Buenos Aires, Argentinagalobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Galobio is a biotechnology company focused on the development of therapies targeting Galectin-1, a key protein involved in immune regulation and vascularization. Founded by Dr. Gabriel Rabinovich, the company builds on over 30 years of research into how Galectin-1 helps tumors evade the immune system and how its modulation can treat inflammatory conditions. Their approach includes developing monoclonal antibodies to block Galectin-1 in oncology and using Galectin-1 variants to treat autoimmune diseases. Galobio represents a significant effort to translate Argentine scientific excellence into global therapeutic products.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Monoclonal antibodyRecombinant protein
- Industry
- Biotech
02
Partnerships
CONICETFundación Sales
Beyond the preview
Go deeper on Galobio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galobio.